Class Effect “Moratorium” Proposed By Harvard’s Avorn; FDA Should “Grow Up”
Executive Summary
FDA should be less reliant on potential class similarities in evaluating safety and efficacy, pharmacoepidemiologist Jerry Avorn (Harvard University) said